SCOTTISH biotechnology company TC BioPharm (TCB) has secured a £500,000 regional selective assistance (RSA) grant to help it develop a treatment for different types of cancer.

The funding will support a strategic collaboration announced by TCB yesterday with MEDINET, a Tokyo-listed immuno-cell therapy company.

Under the deal, MEDINET will licence its innovative cell therapy to TCB exclusively for its clinical development in the UK and Europe.

Loading article content

The technology involves using patients' own immune cells grown in culture to target cancer, and is said to have safely treated patients in Japan.

Under the guidance of professor Jeff Evans, of the University of Glasgow, TCB hopes to treat the first patients in early 2015, working with established cancer clinics in Glasgow and Southampton.

The RSA grant, awarded through Scottish Enterprise (SE), will support the creation of 35 jobs over the next three years. TCB is also working with SE on business planning, investment strategy and international opportunities through Scottish Development International.

It was also announced yesterday that TCB has signed a 10-year lease on a 5000 sq ft site at Eurocentral's Maxim Office Park as its new Scottish base.